|Brooks Automation Announces the Acquisition of Software Assets|
“The RURO software platform enhances our growing portfolio of informatics solutions, providing customers with complete insight into their samples and enabling them to accelerate their research,” said
“Our laboratory freezer sample management software is a perfect complement to Brooks Life Sciences,” said
The acquisition is the latest addition to the growing portfolio of Brooks Life Sciences’ products, services, and informatics. FreezerPro and BioBankPro expand Brooks’ software offerings into a full range of informatics solutions that will now address any size laboratory, biobank or enterprise managing biological samples.
Brooks is a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences. Brooks’ technologies, engineering competencies and global service capabilities provide customers speed to market and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market. Since 2011, Brooks has applied its automation and cryogenics expertise to meet the sample storage needs of customers in the life sciences industry. Brooks’ life sciences offerings include a broad range of products and services for on-site infrastructure for sample management in temperatures of ‑20°C to -150°C, as well as comprehensive outsource service solutions across the complete life cycle of biological samples including collection, transportation, processing, storage, protection, retrieval and disposal. Brooks is headquartered in
“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include, but are not limited to, statements about the anticipated benefits of the acquisition of the RURO assets. Factors that could cause results to differ from our expectations include the following: potential difficulties with the integration of the assets into Brooks Life Science Systems and potential adverse reactions or changes to business relationships resulting from Brooks’ ownership of the acquired assets. In addition, actual results are subject to other risks that relate more broadly to Brooks’ overall business, including those that we have described in our filings with the